J.P. Morgan
The company’s next VC round hinged on Phase I results for QRL-201, an antisense oligonucleotide designed to restore STMN2 expression in ALS patients, and topline data are promising.
While Viridian awaits a US FDA approval decision for veligrotug in thyroid eye disease by June 30, the company will report the first Phase III data for a subcutaneous version, among other 2026 pipeline updates.
Boehringer Ingelheim president of US human pharma Brian Hilberdink said he loves to launch and with up to 20 new product launches planned over the next five years, his team should be busy.
Scrip spoke to global heads of research and early development for oncology, Dominik Ruettinger, and for cardiovascular/renal, Andrea Haegebarth, about Bayer’s strategic focus on precision medicines and key milestones for both therapeutic areas in 2026.
After its ProfoundBio and Merus acquisitions in 2024 and 2025, Genmab could add Rina-S and petosemtamab to its two marketed cancer drugs, Epkinly and Tivdak, before its Darzalex royalty stream dries up.
Given its already large cancer drug pipeline, EVP of oncology R&D Susan Galbraith spoke with Scrip about how AstraZeneca is making precise choices about deals and development programs.
Bristol Myers Squibb execs David Elkins and Adam Lenkowsky spoke with Scrip about the company’s efforts to grow new products and advance novel drugs before Opdivo and Eliquis lose exclusivity in 2028.
Scrip spoke with Novo’s SVPs for global research and global business development, Jacob Petersen and Tamara Darsow, about dealmaking and R&D priorities after the company streamlined to focus more intensely on obesity and diabetes.
Revenue from Sun Pharma’s innovative medicines business overtook its generics business for the first time ever in Q2 of fiscal year 2026 and North American CEO Richard Ascroft is focused on maintaining the growth momentum.
Obesity drug MariTide and olpasiran in cardiovascular disease will not produce Phase III data until 2027, but Scrip spoke with Amgen EVP of R&D James Bradner about those programs, near-term pivotal readouts and dealmaking to boost research capabilities.
The company is getting ready for multiple cancer drug launches, potentially including anti-PD-L1/VEGF pumitamig. Chief commercial officer Annemarie Hanekamp spoke to Scrip.
The company’s chief operating officer and next CEO Karen Massey talked with Scrip about the rise of Vyvgart and how the Dutch biotech is planning for the next phase of growth.
Scrip senior editor Jessica Merrill, Scrip US managing editor Mandy Jackson and In Vivo senior reporter David Wild discuss trends and topics from interviews and presentations at the J.P. Morgan Healthcare Conference and Biotech Showcase.
VP Elizabeth Naldi-Jacob spoke with Scrip at the J.P. Morgan Healthcare Conference about Merck’s business development priorities and the company’s strategy for winning deals.
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Interviews during the J.P. Morgan Healthcare Conference and commentary at the Biotech Showcase foresaw a strong 2026 almost across the board for drug developers seeking funding.
Biogen’s president and head of North America talked to Scrip about the company’s commercial expansion into new areas in immunology and nephrology.
Broad stock market tensions pervaded the atmosphere as the world’s premier healthcare conference got underway.A lack of big-ticket acquisition announcements and continuing drug pricing pressures did nothing to improve stock and index performances.
CEO Ahmed Mousa believes buloxibutid represents a real breakthrough.
Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.